
Thermo Fisher to Upgrade Bioprocessing Operations
Thermo Fisher Scientific plans to spend more than $600 million to upgrade its bioprocessing operations up to 2022. It aims to more than double current manufacturing capacity and support biopharma customers as they ramp up to meet short-term demands related to COVID-19. Another goal is to support its own long-term efforts to develop new vaccines and biologics for other conditions.







































